1-12 of 12
Christophe Le Tourneau
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B005: Impact of molecular profiling and ESCAT classification on patient outcome: The experience of Institut Curie Molecular Tumor Board

Maud Kamal, Kimya Rahmani Narj Abadi, Raphaël Sanchez, Célia Dupain, Isabelle Guillou, Grégoire Marret, Zahra Castel Ajgal, Marie Paule Sablin, Cindy Neuzillet, Amani Asnacios Lecerf, Edith Borcoman, Ségolène Hescot, Florence Coussy, Manuel Rodrigues, Nicolas Girard, Sarah Watson, Julien Masliah Planchon, Jennifer Wong, Abderaouf Hamza, Celine Callens, Olfa Trabelsi Grati, Samia Melaabi, Keltouma Driouch, Emmanuelle Mouret-Fourme, Chrystelle Colas, Samantha Antonio, Odette Mariani, Michèle Nijnikoff, Anne Vincent-Salomon, Yves Allory, Ivan Bieche, Christophe Le Tourneau
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B005.
https://doi.org/10.1158/1535-7163.TARG-23-B005
Published: 01 December 2023
View article titled, Abstract B005: Impact of molecular profiling and ESCAT classification on patient outcome: The experience of Institut Curie Molecular Tumor Board
Journal Articles

Abstract A113: National multidisciplinary tumor board improves diagnostic stratification and therapeutic management in cancers of unknown primary

Ivan Bieche, Maud Kamal, Nicolas Jacquin, Célia Dupain, Isabelle Guillou, Etienne Rouleau, Julien Masliah Planchon, Isabelle Soubeyran, Christelle De La Fouchardière, Camille Tlemsani, Hélène Blons, Laëtitia Marisa, Anna Patrikidou, Fabienne Escande, Pierre Blanc, Jennifer Wong, Pierre Saintigny, Sandrine Boyault, Adrien Buisson, Yves Allory, Anne Vincent-Salomon, Vincent Cockenpot, Janick Selves, Christophe Le Tourneau, Sarah Watson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): A113.
https://doi.org/10.1158/1535-7163.TARG-23-A113
Published: 01 December 2023
View article titled, Abstract A113: National multidisciplinary tumor board improves diagnostic stratification and therapeutic management in cancers of unknown primary
Journal Articles

Abstract B046: A first-in-human Phase 1a/b of PEP-010, a proapoptotic bifunctional peptide, administered as single agent and in combination with paclitaxel in patients with recurrent and/or metastatic solid cancer: results from the dose escalation study

Pauline Du Rusquec, Elodie Coquan, Frederique Berger, Keyvan Rezai, Pierre-Emmanuel Brachet, Sophie Postel-Vinay, Zahra Castel-Ajgal, Gregoire Marret, Marie-Paule Sablin, Segolene Hescot, Raphael Sanchez, Anne-Claire Coyne, Claire Bertrand, Clementine Bouchez, Elsa Lafitte, Lucas Frezouls, Carole Mardesson, Abdelkrim Taamma, Chantal Krezel, Laura Dadon, Christophe Le Tourneau
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B046.
https://doi.org/10.1158/1535-7163.TARG-23-B046
Published: 01 December 2023
View article titled, Abstract B046: A first-in-human Phase 1a/b of PEP-010, a proapoptotic bifunctional peptide, administered as single agent and in combination with paclitaxel in patients with recurrent and/or metastatic solid cancer: results from the dose escalation study
Journal Articles

Abstract IA007: Design of next generation precision medicine trials using artificial intelligence

Christophe Le Tourneau
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): IA007.
https://doi.org/10.1158/1535-7163.TARG-23-IA007
Published: 01 December 2023
View article titled, Abstract IA007: Design of next generation precision medicine trials using artificial intelligence
Journal Articles

Abstract A076: Phase I dose escalation study evaluating the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of AsiDNA, a first-in-class DNA Repair Inhibitor, administered intravenously (IV) in patients with advanced solid tumors

Christophe Le Tourneau, Jean-Pierre Delord, Philippe Cassier, Nuria Kotecki, Edith Borcoman, Ségolène Hescot, Christiane Jungels, Audrey Mole, Hélène Toussaint, Olga Adamiec, Olivier de Beaumont
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A076.
https://doi.org/10.1158/1535-7163.TARG-19-A076
Published: 01 December 2019
View article titled, Abstract A076: Phase I dose escalation study evaluating the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of AsiDNA, a first-in-class DNA Repair Inhibitor, administered intravenously (IV) in patients with advanced solid tumors
Journal Articles

Abstract C2: Clinical safety, pharmacokinetics and early evidence of activity of the oral IAPs inhibitor Debio 1143 in combination with carboplatin and paclitaxel: a phase Ib study

Isabelle Ray-Coquard, Christophe Le Tourneau, Nicolas Isambert, Carlos A. Gomez-Roca, Philippe Cassier, Marie Paule Sablin, Bruno Gavillet, Daniela Purcea, Elisabeth Rouits, Claudia Schusterbauer, Claudio Zanna, Pierre Fumoleau, Jean-Pierre Delord
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C2.
https://doi.org/10.1158/1535-7163.TARG-15-C2
Published: 01 December 2015
View article titled, Abstract C2: Clinical safety, pharmacokinetics and early evidence of activity of the oral IAPs inhibitor Debio 1143 in combination with carboplatin and paclitaxel: a phase Ib study
Journal Articles

Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort

Miguel Quintela-Fandino, Christophe Le Tourneau, Ignacio Duran, Eric X. Chen, Lisa Wang, Ming Tsao, Bizhan Bandarchi-Chamkhaleh, Nhu-Ann Pham, Trevor Do, Martha MacLean, Rakesh Nayyar, Michael W. Tusche, Ur Metser, John J. Wright, Tak W. Mak, Lillian L. Siu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (3): 751–760.
https://doi.org/10.1158/1535-7163.MCT-09-0868
Published: 09 March 2010
View article titled, Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort
Open the PDF for Phase I Combination of Sorafenib and Erlotinib Therapy in Solid Tumors: Safety, Pharmacokinetic, and Pharmacodynamic Evaluation from an Expansion Cohort in another window
Journal Articles

Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells

Maria Serova, Aïda Ghoul, Karim A. Benhadji, Sandrine Faivre, Christophe Le Tourneau, Esteban Cvitkovic, Francois Lokiec, Janet Lord, Steven M. Ogbourne, Fabien Calvo, Eric Raymond
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (4): 915–922.
https://doi.org/10.1158/1535-7163.MCT-07-2060
Published: 15 April 2008
View article titled, Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells
Open the PDF for Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells in another window
Journal Articles

AS703569, a novel aurora kinase inhibitor, enhances the antiproliferative effects of other targeted therapies in human cancer cell lines

Maria Serova, Nasredine Aissat, Aida Ghoul, Christophe Le Tourneau, Angela Romanelli, Athos Gianella-Borradori, Esteban Cvitkovic, Eric Raymond, sandrine faivre
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C188.
Published: 01 November 2007
View article titled, AS703569, a novel aurora kinase inhibitor, enhances the antiproliferative effects of other targeted therapies in human cancer cell lines
Journal Articles

Cellular and molecular mechanisms of action of AS703569, a novel aurora kinase inhibitor, in human cancer cell lines

Nasredine Aissat, Maria Serova, Aida Ghoul, Christophe Le Tourneau, Angela Romanelli, Athos Gianella-Boradorri, Esteban Cvitovic, Sandrine Faivre, Eric Raymond
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C197.
Published: 01 November 2007
View article titled, Cellular and molecular mechanisms of action of AS703569, a novel aurora kinase inhibitor, in human cancer cell lines
Journal Articles

Antiproliferative activity of AS703569, a novel aurora kinase inhibitor, given as a single agent and in combination with EGFR inhibitors in human head and neck squamous cell carcinoma (HNSCC).

Nasredine Aissat, Maria Serova, Aida Ghoul, Ivan Bieche, Michel Vidaud, Christophe Le Tourneau, Angela Romanelli, athos gianella-borradori, Esteban Cvitovic, Eric Raymond, Sandrine Faivre
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C194.
Published: 01 November 2007
View article titled, Antiproliferative activity of AS703569, a novel aurora kinase inhibitor, given as a single agent and in combination with EGFR inhibitors in human head and neck squamous cell carcinoma (HNSCC).
Journal Articles

Resistance to PKCδ activators yield an increased endothelin-1-mediated invasive phenotype in human cancer cells

Aida Ghoul, Maria Serova, Ivan Bieche, Nasredine Aissat, Christophe Le Tourneau, Michel Vidaud, Francois Lokiec, Eric Raymond, Sandrine Faivre
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A183.
Published: 01 November 2007
View article titled, Resistance to PKCδ activators yield an increased endothelin-1-mediated invasive phenotype in human cancer cells